TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11880968
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (indinavir or nelfinavir with zidovudine and lamivudine)
Study: 7477806
Drug: Psychopharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological treatment (details not provided)
Study: 2080934
Drug: Calcitonin nasal
Normalized name: calcitonin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin nasal spray (200 IU intranasal daily for one year)
Study: 531075
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral methadone
Study: 6770400
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral methadone
Study: 16757527
Drug: rhGH (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH (6 mg daily injection for 3 months)
Study: 16757527
Drug: Placebo (self-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (self-administered for 3 months)
Study: 11522739
Drug: Cooked green
Normalized name: egg shell, cooked
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooked green banana (250 g/L)
Study: 11522739
Drug: Pectin (4
Normalized name: amylopectin (4,5-dihydroxy-1,3-dimethylimdazolidin-2-one cross linked)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (4 g/kg)
Study: 8280545
Drug: Oral bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromfenac 10 mg
Study: 8280545
Drug: Oral bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bromfenac 25 mg
Study: 29377474
Drug: Eculizumab (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (single dose prior to transplantation)
Study: 25597173
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (200 IU/d) and calcium (600 mg/d)
Study: 25597173
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (100 mg) and vitamin C (100 mg)
Study: 20439627
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen (CEE; 0.625 mg/d)
Study: 12814319
Drug: 2 IMZ
Normalized name: Imidazole
DrugBank: Imidazole (DB03366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IMZ implants placed in a single-stage procedure
Study: 12814319
Drug: 2 IMZ
Normalized name: Imidazole
DrugBank: Imidazole (DB03366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 IMZ implants placed in the traditional 2-stage procedure
Study: 12814319
Drug: 2 ITI
Normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ITI implants (single-stage procedure)
Study: 8794418
Drug: Replens (non-hormonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replens (non-hormonal moisturizing vaginal gel) applied three times a week for 12 weeks
Study: 8794418
Drug: Dienoestrol (oestrogenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dienoestrol (oestrogenic vaginal cream) administered daily for the first 2 weeks and then three times a week
Study: 1638171
Drug: L-deprenyl (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-deprenyl (5 mg twice a day for 60 days)
Study: 28166806
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT‐A) injections in the calf muscles
Study: 28166806
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline injections in the calf muscles (placebo)
Study: 24861802
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus weekly post‐discharge breastfeeding telephone support (20-30 minutes for 4 weeks)
Study: 22038209
Drug: Postoperative enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative enteral nutrition (EN) with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC)
Study: 22038209
Drug: Postoperative parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative parenteral nutrition (PN) with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC)
Study: 19744620
Drug: Brain natriuretic
Normalized name: Brain natriuretic peptide
DrugBank: .gamma.-brain natriuretic peptide (DB19026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain natriuretic peptide (BNP) > or = 105 pg/ml
Study: 17686797
Drug: Pragmatic group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pragmatic group: no aspiration, rapid injection and rapid withdrawal
Study: 17686797
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care group: slow aspiration prior to injection, slow injection and slow withdrawal
Study: 9753050
Drug: 100 mg/d
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/d aspirin for 2 weeks
Study: 7800210
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg acetylsalicylic acid daily (group B)
Study: 27774990
Drug: Pomalidomide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2.0 mg/day in cohort 1
Study: 27774990
Drug: Pomalidomide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 0.5 mg/day in cohort 2
Study: 27774990
Drug: Pomalidomide 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 2.0 mg/day
Study: 23435671
Drug: non-erlotinib containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-erlotinib containing 2nd-line chemotherapy
Study: 22078721
Drug: Oral amoxicillin
Normalized name: amoxicillin Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amoxicillin (80-90 mg/kg per day or 375 mg twice a day for infants aged 2-11 months and 625 mg twice a day for those aged 12-59 months)
Study: 22078721
Drug: First dose
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: First dose of oral co-trimoxazole (sulfamethoxazole 200 mg plus trimethoprim 40 mg for age 2-11 months; sulfamethoxazole 300 mg plus trimethoprim 60 mg for age 12 months to 5 years) and referral to health facility
Study: 22078721
Drug: Oral co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-trimoxazole
Study: 19321570
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/d) with vitamin D (16 microg/d) and calcium (700 mg/d) in women
Study: 19321570
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/d) with vitamin D (16 microg/d) and calcium (700 mg/d) in men
Study: 19321570
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with vitamin D (16 microg/d) and calcium (700 mg/d) in women
Study: 19321570
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/d)
Study: 19321570
Drug: DHEA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHEA supplementation (50 mg/d) and placebo
Study: 16296368
Drug: Esmolol 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 0.6 mg x kg(‐1) administered immediately after HB administration
Study: 9567633
Drug: 1 mg/kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg‐1 of lidocaine
Study: 9567633
Drug: 0.5 mg/kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg‐1 of urapidil
Study: 28467113
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 300 U/mL (Gla-300)
Study: 28467113
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Glargine 100 U/mL (Gla-100)
Study: 26051728
Drug: Probiotics combined
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics combined with triple therapy
Study: 26051728
Drug: Traditional triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional triple therapy
Study: 17090560
Drug: Early switch
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early switch to oral antibiotics after 3 days of intravenous antibiotics
Study: 17090560
Drug: Standard 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 7 day course of intravenous antibiotics
Study: 14982610
Drug: Formoterol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (120 microg total metered dose, 90 microg delivered dose)
Study: 14982610
Drug: Salbutamol (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol (2000 microg total metered dose)
Study: 10552274
Drug: 5.5% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.5% carbohydrate (CHO) solution
Study: 31387592
Drug: Curcumin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin supplementation (1000 mg/day)
Study: 23246796
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered carotenoids
Study: 9360530
Drug: Eugonadal state
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eugonadal state (saline injections)
Study: 9360530
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose testosterone (testosterone enanthate, 3 mg/kg.week)
Study: 9360530
Drug: Stanozolol (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol (0.1 mg/kg.day)
Study: 9360530
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose testosterone treatment
Study: 31536041
Drug: Vinpocetine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinpocetine (2 mg/kg/day)
Study: 27512103
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine (2 µg/kg per minute)
Study: 27512103
Drug: Low-dose nesiritide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose nesiritide (0.005 μg/kg per minute without bolus)
Study: 21903032
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg/d for 6 weeks (T0)
Study: 21903032
Drug: Paroxetine 30-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30-50 mg/d for 6 weeks (T1)
Study: 21903032
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment responders
Study: 18830236
Drug: Placebo dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose escalation
Study: 21034206
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy (grief therapy)
Study: 8273216
Drug: Combined Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Group A + B (no treatment control)
Study: 8273216
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment control (Group B)
Study: 28045799
Drug: Brief communication
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief communication skills training (CST) program based on cognitive behavioral therapy (CBT)
Study: 26591680
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) therapy including Daoyin, Tuina, and acupotomology
Study: 18055072
Drug: EP HIV-1090
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EP HIV-1090 vaccine (0.5, 2.0, or 4.0mg doses)
Study: 12892853
Drug: Cognitive‐behavioural therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioural therapy plus enriched treatment‐as‐usual (CBT‐ETAU)
Study: 12892853
Drug: Enriched treatment‐as‐usual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched treatment‐as‐usual only (ETAU)
Study: 11192477
Drug: etodolac 400mg
Normalized name: ETODOLAC 400MG TAB
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac 400mg in solution, given as a single dose over 1 minute
Study: 11192477
Drug: etodolac 400mg
Normalized name: ETODOLAC 400MG TAB
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac 400mg in divided doses over 30 minutes
Study: 11192477
Drug: etodolac 400mg
Normalized name: ETODOLAC 400MG TAB
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac 400mg in divided doses over 90 minutes
Study: 11192477
Drug: Delayed absorption
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed absorption (not specified dosage)
Study: 1285663
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg orally between the 5th and 7th day post MI, sustained until the end of the study.
Study: 1285663
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg capsules t.i.d. started between days 5 and 7 post MI.
Study: 1285663
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment according to the ICCU routine.
Study: 26226166
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) 4 g
Study: 18308795
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg 5-HTP with CBD
Study: 18308795
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg 5-HTP with CBD
Study: 18308795
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg 5-HTP with CBD
Study: 8988064
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg intramuscular ketorolac
Study: 14523887
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg intramuscular ketorolac
Study: 8988064
Drug: 90 mg
Normalized name: papain 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg intramuscular ketorolac
Study: 1596720
Drug: Evening primrose
Normalized name: EVENING PRIMROSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evening primrose oil; treatment improved fatty acid profiles towards normal; specific dosage and duration not mentioned.
Study: 3901218
Drug: Biostim (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biostim (2 mg/day for the first month, 1 mg/day for the second and third months)
Study: 24916319
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy with support to taper/discontinue antidepressant medication (MBCT-TS)
Study: 24916319
Drug: Maintenance antidepressant
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressant treatment (m-ADM)
Study: 16675509
Drug: Ondansetron infusion
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron infusion at 250 ng/ml
Study: 15324521
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus ezetimibe 10 mg (n = 12)
Study: 15324521
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg plus placebo (n = 12)
Study: 15324521
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg plus placebo (n = 8)
Study: 11275915
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy guided by a combination of clinical assessment and hemodynamic monitoring (PAC arm)
Study: 11275915
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy guided by clinical assessment alone (CLIN arm)
Study: 9284842
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (e.g., nifedipine, diltiazem, verapamil)
Study: 9284842
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting formulations and newer calcium channel blockers
Study: 8330066
Drug: Active Specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Specific Immunotherapy (A.S.I.) with autologous irradiated tumor cells mixed with BCG (10^7) injected intradermally on days 28 and 35 after surgery.
Study: 8330066
Drug: Active Specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Specific Immunotherapy (A.S.I.) with autologous irradiated tumor cells alone injected intradermally on day 42 after surgery.
Study: 3791362
Drug: Somophyllin‐CRT (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somophyllin‐CRT (500 mg)
Study: 3791362
Drug: Theo‐Dur (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo‐Dur (600 mg)
Study: 27752827
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT/MED) using R&R2ADHD programme
Study: 26022103
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU/MED)
Study: 26022103
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT/MED)
Study: 25874243
Drug: Panacea (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panacea (sodium diclofenac + carisoprodol + acetaminophen + caffeine)
Study: 11208239
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (fruits, vegetables, low-fat dairy, low total and saturated fat)
Study: 2198812
Drug: 0.25% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% betaxolol suspension
Study: 2351301
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of 160 ml autologous venous blood
Study: 2351301
Drug: Intragastric infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intragastric infusion of 160 ml egg white (Control)
Study: 29051044
Drug: Glucose control
Normalized name: Glucose Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose control therapy
Study: 29051044
Drug: Random assignment
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random assignment to treatment
Study: 9552776
Drug: Trigger point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trigger point injections (TPI) with 1% lidocaine
Study: 2685471
Drug: 3 gms
Normalized name: SODIUM CHLORIDE 600 mg in 100 mL / POTASSIUM CHLORIDE 30 mg in 100 mL / CALCIUM CHLORIDE 20 mg in 100 mL / SODIUM LACTATE 310 mg in 100 mL INTRAPERITONEAL SOLUTION [GMS Electrolyte Solution Compound Sodium Lactate Hartmanns]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 gms L-tryptophan
Study: 18561587
Drug: HESA-A tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HESA-A tablet 25 mg/kg twice a day orally
Study: 7793450
Drug: Inositol 12
Normalized name: inositol 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inositol 12 g/day
Study: 7048671
Drug: Diethylcarbamazine (DEC)
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diethylcarbamazine (DEC) administration during daytime
Study: 19542476
Drug: 4-month treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-month treatment arm
Study: 19542476
Drug: 6-month treatment
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month treatment arm
Study: 17697456
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% formulation A
Study: 17697456
Drug: Prednisolone acetate
Normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone acetate 1% formulation B
Study: 14632962
Drug: Nortriptyline 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline 150 mg/day
Study: 10928310
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (4, 8, 16 mg)
Study: 11351930
Drug: Sublingual buprenorphine/naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine/naloxone (1/0.25, 2/0.5, 4/1, 8/2, 16/4 mg)
Study: 10928310
Drug: Intramuscular hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hydromorphone (2, 4 mg)
Study: 8872617
Drug: Inhaled glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled glucocorticoid therapy (2 x 100 micrograms beclomethasone 4 times/day for 2.5 yr)
Study: 8872617
Drug: No inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: No inhaled glucocorticoid therapy
Study: 6471383
Drug: CET 30
Normalized name: Lancet 30G
Approvals — FDA: no, EMA: no, PMDA: no
Description: CET 30 mg/kg
Study: 6471383
Drug: LMOX 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMOX 30 mg/kg
Study: 6471383
Drug: LMOX 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMOX 20 mg/kg
Study: 14746625
Drug: Griseofulvin 500
Normalized name: griseofulvin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Griseofulvin 500 mg twice daily for 4 weeks
Study: 8186139
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg daily for 4 weeks
Study: 14746625
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg once weekly for 4 weeks
Study: 14746625
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg twice daily for 1 week
Study: 8487051
Drug: Concomitant fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Concomitant fluorouracil (FUra) infusional therapy (1.2 g/m2 per 24 hours)